

29<sup>th</sup> June 2016

Announcements  
National Stock Exchange of Australia  
PO Box 283  
NEWCASTLE NSW 2300

## **iQN –IQX subsidiary acquires Novel Glucose Biosensor**

**iQNovate Ltd (NSX:IQN)** iQN would like to announce that in partnership with IQX Ltd, and through their fully owned subsidiary; Life Science Biosensor Diagnostics Pty Ltd (LSBD), have acquired the Intellectual Property from the University of Newcastle and Newcastle Innovation Ltd, to a novel Glucose Biosensor.

This Biosensor is an Organic Thin Film Transistor (OTFT) platform that is capable of detecting a broad range of glucose levels, it is easy to use and cheap to manufacture.

LSBD will be, as soon as possible, implementing a clinical development program in order to generate efficacy and safety data that will allow for registration as a diagnostic system with the European Regulatory Authorities initially and then globally.

This biosensor platform enables blood glucose concentrations to be estimated by measuring the level of glucose in saliva and correlating the reading with the blood glucose level, hence obviating the need for diabetic patients to obtain a blood sample multiple times a day.

iQN CEO Dr. George Syrmalis was quoted stating “Successful commercialization of this biosensor means that millions of people worldwide will be able to monitor their blood glucose levels without the pain of the needle prick several times a day. Hence we are focusing on bringing this to the market as soon as possible”

According to an industry report by Kalorama information it was estimated that the global glucose monitoring device and diabetes management market was valued in excess of US\$10 billion in 2015 .

## Investor Relations

### For further information, please contact:

iQ3Corp Investor Relations Team  
Email: [investor.relations@iq3corp.com](mailto:investor.relations@iq3corp.com)  
Phone: +61 2 8239 5400

Sydney: Level 7, 222 Clarence Street, Sydney, NSW 2000, Australia • Phone: +61 2 8239 5400  
New York: 400 Madison Avenue, Suite 10A, New York City NY10017 USA | +1 212 433 2630  
London: 20 Broadwick Street, London, W1F-8HT, UK • Phone: +44(0)2077121508

#### *Safe Harbor Statement*

*Any statements in this announcement that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.*

#### **SOURCE IQnovate Ltd**

*IQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.*

*Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.*

*iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.*